-
2026 EHA Academic Frontier: Professor Stephen Ansell Deeply Analyzes the Biological Characteristics and Immune Microenvironment Remodeling of Classical Hodgkin Lymphoma
At the 2026 European Hematology Association (EHA) Annual Meeting, world-renowned lymphoma expert Professor Stephen Ansell from the Mayo Clinic (Rochester, Minnesota, USA) was invited to deliver a keynote speech titled “Deciphering HL biology.” Professor Ansell systematically reviewed the molecular origins of Reed-Sternberg (RS) cells in classical Hodgkin lymphoma (cHL), the abnormal activation of key signaling…
-
EHA 2026 | Interpretation by Professor Todd Knepper: Molecular Surveillance and Clinical Trajectories of Donor-Derived Clonal Hematopoiesis after Allogeneic Hematopoietic Stem Cell Transplantation
At the 2026 European Hematology Association (EHA) Annual Meeting, Professor Todd Knepper from Moffitt Cancer Center shared a thematic report on “Post-Transplant Molecular Surveillance Reveals Divergent Clinical Trajectories of Donor-Derived Clonal Hematopoiesis (DD-CHIP).” Through high-throughput sequencing (NGS) technology, this study explored the incidence, molecular landscape, and differentiated impact of DD-CHIP on clinical outcomes in recipients…
-
Frontline Perspectives from EHA 2026: Iterations in CAR-T Manufacturing Processes and Innovations in Engineering Platforms for Multiple Myeloma
The treatment of multiple myeloma (MM) has entered the era of immunotherapy. In particular, the emergence of Chimeric Antigen Receptor T-cell (CAR-T) therapy has significantly improved the prognosis of patients with relapsed/refractory multiple myeloma (R/R MM). However, challenges such as resistance caused by antigen loss, prolonged manufacturing cycles (vein-to-vein time), and potential severe toxicities remain…
-
2026 EHA Academic Feast: Multiple Myeloma Treatment Enters a New Era of Precision Stratification—From Reshaping ASCT Status to Breaking the Deadlock in Ultra-High Risk Strategies
In June 2026 local time, the European Hematology Association (EHA) Annual Congress was grandly held. In the Multiple Myeloma (MM) session, top global hematology experts engaged in in-depth dialogues regarding the treatment pathways for newly diagnosed multiple myeloma (NDMM), liquid biopsy for prognostic assessment, and intensified treatment regimens for ultra-high risk patients. This session was…
-
EHA Echoes · Voices from China | Prof. Meng Lü: CAR-T vs Antibody-Based Therapy as a Bridge to Transplantation—Defining the Optimal Stratified Approach for R/R B-ALL
In the era of rapidly evolving immunotherapy, determining the optimal bridging strategy to hematopoietic stem cell transplantation (HSCT) for patients with relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL) remains a major clinical challenge. At EHA 2026, Prof. Meng Lü and colleagues from Peking University People’s Hospital presented an important oral study based on a large…
-
EHA Insights | Prof. Shenmiao Yang: Toward a Cure—New Strategies in CLL Through Targeted Combination Therapy
As targeted therapies continue to transform the treatment landscape of chronic lymphocytic leukemia (CLL), therapeutic goals are evolving beyond long-term disease control toward deeper remissions, fixed-duration treatment strategies, and even the possibility of functional cure. At EHA 2026, several landmark studies provided important evidence supporting this paradigm shift.
-
Predicting a 92% pCR: Preoperative Radiotherapy Acts as an “Immune Primer” for High-Risk TNBC in the TBCRC-053 Trial
the field of breast cancer, Triple-Negative Breast Cancer (TNBC) has become a clinical challenge due to its high aggressiveness and lack of effective targets. Although the KEYNOTE-522 study established the standard status of Immune Checkpoint Inhibitors (ICI) combined with chemotherapy in perioperative TNBC, high-risk patients with lymph node-positive and T3/T4 stage disease still face a…
-
Breaking the Dilemma of Margins in Breast-Conserving Surgery: SHAVE Series Research Confirms CSM Significantly Reduces Re-excision Rates, but Long-term Survival Benefit Remains Dominated by Radiotherapy
At the recent American Society of Clinical Oncology (ASCO) Annual Meeting, Professor Anees B. Chagpar, a Professor of Surgery at the Yale School of Medicine, delivered an important special report titled “Does resection of cavity shave margins impact survival in breast cancer patients?”. Based on the famous SHAVE and SHAVE2 randomized controlled trials, the report…
Connecting Medical Expertise through Media